Picture of Atomo Diagnostics logo

AT1 Atomo Diagnostics Share Price

0.000.00%
au flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapNeutral

Momentum

Relative Strength (%)
1m+6.13%
3m-17.93%
6m-35.71%
1yr-15.33%
Volume Change (%)
10d/3m+31.2%
Price vs... (%)
52w High-65%
50d MA+0.53%
200d MA-18.15%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-67.1%
Return on Equity-55.06%
Operating Margin-161.33%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
30th Jun 202530th Jun 2026
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2025 / 2026

Blurred out image of Atomo Diagnostics EPS forecast chart

Profile Summary

Atomo Diagnostics Limited is an Australia-based medical device company. The Company supplies integrated rapid diagnostic test (RDT) devices to the global diagnostic market. The Company’s patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has commercialized a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases, including COVID-19, HIV, viral vs bacterial differentiation and female health. Its products include Atomo HIV Self-Test, AtomoRapid HIV (1&2) and ATOMONOW Pregnancy Test. Its Atomo HIV Self-Test is an integrated, blood-based rapid diagnostic test (RDT) for HIV screening, which provides results in 15 minutes. Its AtomoRapid HIV (1&2) integrates multiple test components into the device platform. AtomoRapid HIV (1&2) needs a small drop of blood to give results in 15 minutes.

Directors

Last Annual
June 30th, 2024
Last Interim
June 30th, 2024
Incorporated
April 1st, 2010
Public Since
April 16th, 2020
No. of Shareholders
6,850
Sector
Healthcare Equipment & Supplies
Industry
Healthcare
Exchange
au flag iconAustralian Stock Exchange - SEATS
Shares in Issue
639,202,310

AT1 Share Price Performance

Upcoming Events for AT1

Atomo Diagnostics Ltd Annual Shareholders Meeting

Half Year 2025 Atomo Diagnostics Ltd Earnings Release

Similar to AT1

Picture of 4DMedical logo

4DMedical

au flag iconAustralian Stock Exchange - SEATS

Picture of Adherium logo

Adherium

au flag iconAustralian Stock Exchange - SEATS

Picture of Allegra Medical Technologies logo

Allegra Medical Technologies

au flag iconAustralian Stock Exchange - SEATS

Picture of Ansell logo

Ansell

au flag iconAustralian Stock Exchange - SEATS

Picture of Anteris Technologies logo

Anteris Technologies

au flag iconAustralian Stock Exchange - SEATS

FAQ